Alertix
Kalmar
About Alertix
Alertix Veterinary Diagnostics AB was founded in 2017. The goal of the company is to commercialize discoveries from Swedish veterinary medical biotech research. In particular concerning a new, powerful method for measuring the presence of the enzyme thymidine kinase 1 (TK1) in serum of animals important in veterinary medicine. TK1 is a biomarker for tumor growth and cell turnover. The substance has been detected in serum of patients even before they show clinical symptoms. This means that the assay can be a valuable tool for early diagnosis of cancer diseases. Unlike previously established methods for detecting TK1 the Alertix method is an immunochemical routine method, which can also successfully detect serum TK1 in patients with solid tumors.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $407.9K
- Last round: Series Unknown (Sep 2020)
- Website: alertixvet.com
- Phone: 559095-7477
Industries & Categories
Biotechnology, Health Care, Pet, Veterinary
Social Profiles
Canonical: https://fsome.com/organization/alertix-102134 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.